Predictors of Multiple Primary Malignancies: Literature Review
A. V. Sultanbaev,
K. V. Menshikov,
Sh. I. Musin,
A. A. Izmailov,
I. A. Menshikova,
N. I. Sultanbaeva https://doi.org/10.24060/2076-3093-2023-13-3-221-228
Abstract
The present paper considers the predictors of multiple primary malignancies. The multiple primary malignancies are often induced by genetic predisposition and familial cancer syndromes, environmental carcinogens and bad habits (e.g. tobacco and alcohol abuse), immunodeficiency and infectious diseases, carcinogens occurring as a result of various treatments, etc. Germinal mutations are considered to be one of the causes of primary cancer — they increase the risk of various multiple primary malignancies. Hereditary cancers are characterized by a strong family history, early age of onset and occurrence of multiple primary malignancies. The paper considers various mechanisms of multiple primary malignancies with an emphasis on the effect of carcinogens in carriers of pathogenic genes on cancer development. In proven cases, when patients are exposed to multiple carcinogens, they should be aware of possible late and long-term effects of treatment and their symptoms, as well as secondary malignancies that might occur. When the main predictors of carcinogenesis are manageable, and primary preventive measures can be taken, the hereditary malignancies require postexposure prophylaxis. In addition to specific recommendations for the prevention of primary cancers, it is essential to follow recommendations for the prevention of second primary cancers.
About the Authors
A. V. Sultanbaev
Republican Clinical Oncology Dispensary
Russian Federation
Russian Federation
Alexander V. Sultanbaev - Cand. Sci. (Med.), Anticancer Drug Therapy Unit
Ufa
K. V. Menshikov
Republican Clinical Oncology Dispensary; Bashkir State Medical University
Russian Federation
Russian Federation
Konstantin V. Menshikov - Cand. Sci. (Med.), Assoc. Prof., Department of Oncology with Courses of Oncology and Pathological Anatomy for Advanced Professional Education, Chemotherapy Unit
Ufa
Sh. I. Musin
Republican Clinical Oncology Dispensary
Russian Federation
Russian Federation
Shamil I. Musin - Cand. Sci. (Med.), Surgery Unit No. 6
Ufa
A. A. Izmailov
Republican Clinical Oncology Dispensary
Russian Federation
Russian Federation
Adel A. Izmailov - Dr. Sci. (Med.),
Ufa
I. A. Menshikova
Bashkir State Medical University
Russian Federation
Russian Federation
Irina A. Menshikova - Cand. Sci. (Med.), Assoc. Prof., Department of Biological Chemistry
Ufa
N. I. Sultanbaeva
Republican Clinical Oncology Dispensary
Russian Federation
Russian Federation
Nadezhda I. Sultanbaeva - Anticancer Drug Therapy Unit No. 1
Ufa
References
1. Sultanbaev A.V., Nasretdinov A.F., Sultanbaeva N.I., Menshikov K.V., Musin S.I., Izmailov A.A., et al. Sequential anticancer therapy in a patient with metachronous primary uterine cancer and breast cancer. Malignant tumours. 2020;10(4):38–46 (In Russ.). DOI: 10.18027/2224-5057-2020-10-3
2. Chissov V.I., Starinsky V.V., Petrova G.V. (ed.) State of cancer care for population in Russia in 2011. М.: P.A Gertsen Moscow Research Oncology Institute; 2012 (In Russ.).
3. Domozhirova A.S., Bekhtereva S.A., Aksenova I.A. Analysis of the overall survival of patients with primary multiple tumors of the reproductive system in women in the Chelyabinsk region at the population level. Bulletin of the Russian scientifi c center of roentgen radiology. 2020;20(4):39–61 (In Russ.).
4. Behtereva S.A., Vazhenin A.V., Domozhirova A.S. Epidemiological aspects of primary multiple breast cancer based on survival analysis. P.A. Herzen Journal of Oncology. 2020;9(2):48–52 (In Russ.) DOI: 10.17116/onkolog2020902148
5. Pushkarev A.V., Pushkarev V.A., Galeev M.G., Izmailov A.A., Sultanbaeva N.I., Musin Sh.I., et al. Primary-multiple metachronic cancer associated with mutation in the BRCA-1 gene (case in clinical practice). Oncology bulletin of Volga region. 2021;12(1):43–49 (In Russ.).
6. Sultanbaev A.V., Menshikov K., Musin Sh., Nasretdinov A., Sultanbaeva N., Menshikova I., et al. Territorial manifestation features of multiple primary malignant neoplasms in carriers of germline mutations in the BRCA 1 gene in Republic of Bashkortostan. J Clin Oncol. 2022;40(16_suppl):e22523. DOI: 10.1200/JCO.2022.40.16_suppl.e22523
7. Hawkins M., Bhatia S., Henderson T.O., Nathan P.C., Yan A., Teepen J.C., et al. Subsequent primary neoplasms: risks, risk factors, surveillance, and future research. Pediatr Clin North Am. 2020;67(6):1135–54. DOI: 10.1016/j.pcl.2020.07.006
8. Kong Y., Li J., Lin H., Liang X., Zhou X. Landscapes of synchronous multiple primary cancers detected by next-generation sequencing. FEBS Open Bio. 2022;12(11):1996–2005. DOI: 10.1002/2211-5463.13491
9. Fraumeni J.F., Curtis R.E., Edwards B.K., Tucker M.A. Introduction. In: Curtis R.E., Freedman D.M., Ron E., et al. (eds) New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. Bethesda: National Cancer Institute; 2006, pp. 1–8.
10. Rykov M.Yu., Polyakov V.G. Analysis of key indicators of cancer care to the population of Russia. Problems in Oncology. 2015;61(5):750–2 (In Russ.).
11. Shunko E.L., Vazhenin A.V., Shanazarov N.A. Present state of the problem development primary multiple cancer (literature review). Modern problems of science and education. 2015;(10-3):503–6 (In Russ.).
12. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (ed.) State of cancer care for population in Russia in 2021. P.A Gertsen Moscow Research Oncology Institute — branch of the National Medical Research Center for Radiology; 2022 (In Russ.).
13. Adjei Boakye E., Wang M., Sharma A., Jenkins W.D., Osazuwa-Peters N., Chen B., et al. Risk of second primary cancers in individuals diagnosed with index smoking- and non-smoking- related cancers. J Cancer Res Clin Oncol. 2020;146(7):1765–79. DOI: 10.1007/s00432-020-03232-8
14. Schuller H.M. The impact of smoking and the infl uence of other factors on lung cancer. Expert Rev Respir Med. 2019;13(8):761–9. DOI: 10.1080/17476348.2019.1645010
15. Maomao C., He L., Dianqin S., Siyi H., Xinxin Y., Fan Y., et al. Current cancer burden in China: epidemiology, etiology, and prevention. Cancer Biol Med. 2022;19(8):1121–38. DOI: 10.20892/j.issn.2095-3941.2022.0231
16. Larsson S.C., Carter P., Kar S., Vithayathil M., Mason A.M., Michaëlsson K., et al. Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participants. PLoS Med. 2020;17(7):e1003178. DOI: 10.1371/journal.pmed.1003178
17. Recalde M., Davila-Batista V., Díaz Y., Leitzmann M., Romieu I., Freisling H., et al. Body mass index and waist circumference in relation to the risk of 26 types of cancer: a prospective cohort study of 3.5 million adults in Spain. BMC Med. 2021;19(1):10. DOI: 10.1186/s12916-020-01877-3
18. Vaidya R., Till C., Greenlee H., Hershman D.L., Unger J.M. Trends in obesity prevalence among patients enrolled in Clinical Trials for obesity-related cancers, 1986 to 2016. JAMA Netw Open. 2022;5(10):e2234445. DOI: 10.1001/jamanetworkopen.2022.34445
19. Copur M.S., Manapuram S. Multiple primary tumors over a lifetime. Oncology (Williston Park). 2019;33(7):629384. PMID: 31365752.
20. Katirachi S.K., Grønlund M.P., Jakobsen K.K., Gronhoj C., von Buchwald C. The prevalence of HPV in oral cavity squamous cell carcinoma. Viruses. 2023;15(2):451. DOI: 10.3390/v15020451
21. Cavers D., Duff R., Bikker A., Barnett K., Kanguru L., Weller D., et al. Patient and GP experiences of pathways to diagnosis of a second primary cancer: a qualitative study. BMC Cancer. 2021;21(1):496. DOI: 10.1186/s12885-021-08238-0
22. Turcotte L.M., Liu Q., Yasui Y., Henderson T.O., Gibson T.M., Leisenring W., et al. Chemotherapy and risk of subsequent malignant neoplasms in the childhood cancer survivor study cohort. J Clin Oncol. 2019;37(34):3310–9. DOI: 10.1200/JCO.19.00129
23. Berrington de Gonzalez A., Curtis R.E., Gilbert E., Berg C.D., Smith S.A., Stovall M., et al. Second solid cancers aft er radiotherapy for breast cancer in SEER cancer registries. Br J Cancer. 2010;102(1):220–6. DOI: 10.1038/sj.bjc.6605435
24. Dracham C.B., Shankar A., Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J. 2018;36(2):85–94. DOI: 10.3857/roj.2018.00290
25. Leone G., Pagano L., Ben-Yehuda D., Voso M.T. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007;92(10):1389–98. DOI: 10.3324/haematol.11034
26. Azarova A.M., Lyu Y.L., Lin C.P., Tsai Y.C., Lau J.Y., Wang J.C., et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A. 2007;104(26):11014–9. DOI: 10.1073/pnas.0704002104
27. Groot H.J., van Leeuwen F.E., Lubberts S., Horenblas S., de Wit R., Witjes J.A., et al. Platinum exposure and cause-specifi c mortality among patients with testicular cancer. Cancer. 2020;126(3):628–39. DOI: 10.1002/cncr.32538
28. Menshikov K.V., Pushkarev A.V., Sultanbaev A.V., Pushkarev V.A., Sharifgaliev I.A. Radiogenic vaginal angiosarcoma: a clinical case. Creative surgery and oncology. 2020;10(2):143–8 (In Russ.) DOI: 10.24060/2076-3093-2020-10-2-143-148
29. Inskip P.D., Ries L.A., Cohen R.J., Curtis R.E. New malignancies following childhood cancer. In: Curtis R.E., Freedman D.M., Ron E., et al. (eds) New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. Bethesda, MD: National Cancer Institute; 2006, pp. 465–482.
30. Kolyadina I.V., Kometova V.V., Bikeev Yu.V., Khokhlova S.V., Rodionov V.V. Radio-induced breast angiosarcoma: features of diagnostics and treatment (a clinical case and literature review). Tumors of female reproductive system. 2020;16(2):38–43 (In Russ.). DOI: 10.17650/1994-4098-2020-16-2-38-43
31. Blok J.M., Groot H.J., Huele E.H., de Wit R., Horenblas S., Nuver J., et al. Dose-dependent eff ect of platinum-based chemotherapy on the risk of metachronous contralateral testicular cancer. J Clin Oncol. 2021;39(4):319–27. DOI: 10.1200/JCO.20.02352
32. Tibana T.K., Santos R.F.T., Arão Filho A., Bacelar B., Martins L.A., de Souza R.O., et al. Detection of additional primary malignancies: the role of CT and PET/CT combined with multiple percutaneous biopsy. Radiol Bras. 2019;52(3):166–71. DOI: 10.1590/0100-3984.2018.0024
33. Tie J., Kinde I., Wang Y., Wong H.L., Roebert J., Christie M., et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26(8):1715–22. DOI: 10.1093/annonc/mdv177
34. Tie J., Cohen J.D., Lahouel K., Lo S.N., Wang Y., Kosmider S., et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261–72. DOI: 10.1056/NEJMoa2200075
35. Tie J., Wang Y., Tomasetti C., Li L., Springer S., Kinde I., et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92. DOI: 10.1126/scitranslmed.aaf6219
36. Tanjak P., Suktitipat B., Vorasan N., Juengwiwattanakitti P., Thiengtrong B., Songjang C., et al. Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study. BMC Cancer. 2021;21(1):1045. DOI: 10.1186/s12885-021-08766-9
37. Cybulski C., Nazarali S., Narod S.A. Multiple primary cancers as a guide to heritability. Int J Cancer. 2014;135(8):1756–63. DOI: 10.1002/ijc.28988
38. Phillips K.A., Milne R.L., Rookus M.A., Daly M.B., Antoniou A.C., Peock S., et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31(25):3091–9. DOI: 10.1200/JCO.2012.47.8313
39. Malla M., Loree J.M., Kasi P.M., Parikh A.R. Using circulating tumor DNA in colorectal cancer: current and evolving practices. J Clin Oncol. 2022;40(24):2846–57. DOI: 10.1200/JCO.21.02615
40. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789–99. DOI: 10.1038/nm1087. PMID: 15286780.
41. Rahman N. Realizing the promise of cancer predisposition genes. Nature. 2014;505(7483):302–8. DOI: 10.1038/nature12981
42. Ghose A., Bolina A., Mahajan I., Raza S.A., Clarke M., Pal A., et al. Hereditary ovarian cancer: towards a cost-eff ective prevention strategy. Int J Environ Res Public Health. 2022;19(19):12057. DOI: 10.3390/ijerph191912057
43. Neven P., Punie K., Wildiers H., Willers N., Van Ongeval C., Van Buggenhout G., et al. Risk-reducing mastectomy in BRCA carriers: survival is not the issue. Breast Cancer Res Treat. 2020 Jan;179(1):251–2. DOI: 10.1007/s10549-019-05440-4
44. Jeff ers L., Reid J., Fitzsimons D., Morrison P.J., Dempster M. Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery. Cochrane Database Syst Rev. 2019;10(10):CD012894. DOI: 10.1002/14651858.CD012894.pub2
45. King M.C., Marks J.H., Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–6. DOI: 10.1126/science.1088759
46. Michaelson-Cohen R., Cohen M.J., Cohen C., Greenberg D., Shmueli A., Lieberman S., et al. Real world cost-eff ectiveness analysis of population screening for BRCA variants among Ashkenazi jews compared with family history-based strategies. Cancers (Basel). 2022;14(24):6113. DOI: 10.3390/cancers14246113
47. Li J., Zhao B., Huang T., Qin Z., Wang S.M. Human BRCA pathogenic variants were originated during recent human history. Life Sci Alliance. 2022 Feb 14;5(5):e202101263. DOI: 10.26508/lsa.202101263
48. Ormond K.E., Cho M.K. Translating personalized medicine using new genetic technologies in clinical practice: the ethical issues. Per Med. 2014;11(2):211–22. DOI: 10.2217/pme.13.104
49. Marshall E. Intellectual property. In a fl urry of metaphors, justices debate a limit on gene patents. Science. 2013;340(6131):421. DOI: 10.1126/science.340.6131.421
50. Jung K.Y., Kim S.M., Kim M.J., Cho S.W., Kim B.W., Lee Y.S., et al. Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in Korea. Surgery. 2018;164(2):312–8. DOI: 10.1016/j.surg.2018.03.018
51. Melmon K.L., Rosen S.W. Lindau's disease. Review of the literature and study of a large kindred. Am J Med. 1964;36:595–617. DOI: 10.1016/0002-9343(64)90107-x
52. Cybulski C., Nazarali S., Narod S.A. Multiple primary cancers as a guide to heritability. Int J Cancer. 2014;135(8):1756–63. DOI: 10.1002/ijc.28988
53. Ranola J.M.O., Tsai G.J., Shirts B.H. Exploring the eff ect of ascertainment bias on genetic studies that use clinical pedigrees. Eur J Hum Genet. 2019;27(12):1800–7. DOI: 10.1038/s41431-019-0467-5
54. Lynch P.M., Pande M. Refi ning risk estimates in hereditary nonpolyposis colorectal cancer: are we there yet? JNCI Cancer Spectr. 2020;4(5):pkaa030. DOI: 10.1093/jncics/pkaa030
55. Pilarski R., Burt R., Kohlman W., Pho L., Shannon K.M., Swisher E. Cowden Syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013;105(21):1607–16. DOI: 10.1093/jnci/djt277
56. Sutcliff e E.G., Stettner A.R., Miller S.A., Solomon S.R., Marshall M.L., Roberts M.E., et al. Diff erences in cancer prevalence among CHEK2 carriers identifi ed via multi-gene panel testing. Cancer Genet. 2020;246–247:12–7. DOI: 10.1016/j.cancergen.2020.07.001
57. Choe J.H., Kawase T., Xu A., Guzman A., Obradovic A.Z., Low-Calle A.M., et al. Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death. Cancer Discov. 2023 Apr 17:OF1–24. DOI: 10.1158/2159-8290.CD-22-0882
58. Kimura H., Klein A.P., Hruban R.H., Roberts N.J. The role of inherited pathogenic CDKN2A variants in susceptibility to pancreatic cancer. Pancreas. 2021;50(8):1123–30. DOI: 10.1097/MPA.0000000000001888
59. Arslan Ates E., Alavanda C., Demir S., Keklikkıran C., Attaallah W., Özdoğan O.C., et al. Mutation spectrum of familial adenomatous polyposis patients in turkish population: identifi cation of 3 novel APC mutations. Turk J Gastroenterol. 2022;33(2):81–7. DOI: 10.5152/tjg.2021.201068
60. Campos F.G., Martinez C.A.R., Sulbaran M., Bustamante-Lopez L.A., Safatle-Ribeiro A.V. Upper gastrointestinal neoplasia in familial adenomatous polyposis: prevalence, endoscopic features and management. J Gastrointest Oncol. 2019;10(4):734–44. DOI: 10.21037/jgo.2019.03.06
61. Soons E., Siersema P.D., van Lierop L.M.A., Bisseling T.M., van Kouwen M.C.A., Nagtegaal I.D., et al. Laboratory variation in the grading of dysplasia of duodenal adenomas in familial adenomatous polyposis patients. Fam Cancer. 2023;22(2):177–86. DOI: 10.1007/s10689-022-00320-1
62. Stanich P.P., Pearlman R., Hinton A., Gutierrez S., LaDuca H., Hampel H., et al. Prevalence of germline mutations in polyposis and colorectal cancer-associated genes in patients with multiple colorectal polyps. Clin Gastroenterol Hepatol. 2019;17(10):2008–15.e3. DOI: 10.1016/j.cgh.2018.12.008
63. Murphy A., Solomons J., Risby P., Gabriel J., Bedenham T., Johnson M., et al. Germline variant testing in serrated polyposis syndrome. J Gastroenterol Hepatol. 2022;37(5):861–9. DOI: 10.1111/jgh.15791
64. Volkov N.M., Yanus G.A., Ivantsov A.O., Moiseenko F.V., Matorina O.G., Bizin I.V., et al. Effi cacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer. Invest New Drugs. 2020;38(3):894–8. DOI: 10.1007/s10637-019-00842-z
65. Abdelmaksoud-Dammak R., Miladi-Abdennadher I., Amouri A., Tahri N., Ayadi L., Khabir A., et al. High prevalence of the c.1227_1228dup (p.Glu410GlyfsX43) mutation in Tunisian families aff ected with MUTYH-associated-polyposis. Fam Cancer. 2012;11(3):503–8. DOI: 10.1007/s10689-012-9543-5
66. Lubbe S.J., Di Bernardo M.C., Chandler I.P., Houlston R.S. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol. 2009;27(24):3975–80. DOI: 10.1200/JCO.2008.21.6853
67. Kaurah P., MacMillan A., Boyd N., Senz J., De Luca A., Chun N., et al. Founder and recurrent CDH1 mutations in families with hereditary diff use gastric cancer. JAMA. 2007;297(21):2360–72. DOI: 10.1001/jama.297.21.2360
68. Xicola R.M., Li S., Rodriguez N., Reinecke P., Karam R., Speare V., et al. Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J Med Genet. 2019;56(12):838–43. DOI: 10.1136/jmedgenet-2019-105991
Review
For citations:
Sultanbaev A.V., Menshikov K.V., Musin Sh.I., Izmailov A.A., Menshikova I.A., Sultanbaeva N.I. Predictors of Multiple Primary Malignancies: Literature Review. Creative surgery and oncology. 2023;13(3):221-228. (In Russ.) https://doi.org/10.24060/2076-3093-2023-13-3-221-228
Views:
1172
Email this article 